GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (FRA:MX6A) » Definitions » EV-to-Revenue

Grand Pharmaceutical Group (FRA:MX6A) EV-to-Revenue : 2.49 (As of May. 22, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Grand Pharmaceutical Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Grand Pharmaceutical Group's enterprise value is €3,502 Mil. Grand Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €1,407 Mil. Therefore, Grand Pharmaceutical Group's EV-to-Revenue for today is 2.49.

The historical rank and industry rank for Grand Pharmaceutical Group's EV-to-Revenue or its related term are showing as below:

FRA:MX6A' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.21   Med: 2.07   Max: 4.38
Current: 2.66

During the past 13 years, the highest EV-to-Revenue of Grand Pharmaceutical Group was 4.38. The lowest was 1.21. And the median was 2.07.

FRA:MX6A's EV-to-Revenue is ranked worse than
53.63% of 977 companies
in the Drug Manufacturers industry
Industry Median: 2.37 vs FRA:MX6A: 2.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-22), Grand Pharmaceutical Group's stock price is €0.925. Grand Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.40. Therefore, Grand Pharmaceutical Group's PS Ratio for today is 2.30.


Grand Pharmaceutical Group EV-to-Revenue Historical Data

The historical data trend for Grand Pharmaceutical Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group EV-to-Revenue Chart

Grand Pharmaceutical Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 2.76 1.92 1.46 1.55

Grand Pharmaceutical Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.92 - 1.46 - 1.55

Competitive Comparison of Grand Pharmaceutical Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's EV-to-Revenue falls into.


;
;

Grand Pharmaceutical Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Grand Pharmaceutical Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3501.915/1407.018
=2.49

Grand Pharmaceutical Group's current Enterprise Value is €3,502 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €1,407 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group  (FRA:MX6A) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Grand Pharmaceutical Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.925/0.402
=2.30

Grand Pharmaceutical Group's share price for today is €0.925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was €0.40.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.

Grand Pharmaceutical Group Headlines

No Headlines